Waldencast is voluntarily delisting its shares and warrants from Nasdaq and deregistering them under the Exchange Act, effective October 2026. The company plans to rename itself Milk Makeup plc and seek quotation on an over-the-counter market, signaling a significant shift in its public market presence and investor accessibility.
Waldencast is undertaking a significant corporate restructuring by voluntarily delisting from Nasdaq and deregistering its securities. This move, coupled with the proposed renaming to Milk Makeup plc after the Obagi Medical sale, indicates a strategic pivot to focus solely on the Milk Makeup brand. The delisting will likely reduce liquidity and accessibility for investors, potentially leading to a negative short-term impact on the stock price as some institutional investors may be restricted from holding OTC-traded securities. Long-term implications depend on the success of the Milk Makeup brand as a standalone entity and its ability to attract investors in the OTC market. For traders, the key risk is the immediate liquidity crunch and potential price discovery challenges as the stock transitions from a major exchange to the OTC market.